학술논문

Synergistic effect of temozolomide and thymoquinone on human glioblastoma multiforme cell line (U87MG).
Document Type
Journal Article
Source
Journal of Cancer Research & Therapeutics. Jul-Sep2018, Vol. 14 Issue 5, p1023-1028. 6p.
Subject
*Glioblastoma multiforme
*Temozolomide
*Drug resistance
*Matrix metalloproteinases
*Astrocytes
*Cell lines
*Cell physiology
*Cell motility
*Drug synergism
*Genes
*Gliomas
*Proteolytic enzymes
*Questionnaires
*Benzoquinones
*Dacarbazine
*Arthritis Impact Measurement Scales
*Pharmacodynamics
Language
ISSN
0973-1482
Abstract
Aims: Temozolomide (TMZ) is an alkylating agent used for glioblastoma multiforme (GBM) treatment. Nevertheless, resistance to TMZ is a major obstacle to successful treatment of this cancer. The aim of the present study was to investigate the effects of TMZ and thymoquinone (TQ) on U87MG cell line.Materials and Methods: The effect of TMZ and/or TQ on viability and invasion potential of U87MG cells was evaluated using various techniques including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, lactate dehydrogenase activity, cell invasion, migration, and adhesion assays. Enzyme-linked immunosorbent assay and polymerase chain reaction were used to study the expression and secretion of matrix metalloproteinases (MMPs).Results: Combination of TMZ and TQ had a synergistic cytotoxic effect on U87MG cells. TMZ and/or TQ significantly reduced the potential of U87MG cells invasion. In addition, after treating with TMZ and/or TQ, there was a decrease in the levels of matrix matrix metalloproteinase 2 nad 9 (MMP 2 and 9) expression and secretion in U87MG cells.Conclusions: The combination of TMZ and TQ may emerge as a promising strategy for the successful treatment of GBM. [ABSTRACT FROM AUTHOR]